Prot #CG2003C: A Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

Project: Research project

Project Details

StatusActive
Effective start/end date3/25/21 → 3/25/24

Funding

  • Catalyst Clinical Research, LLC (Prot #CG2003C)
  • CG Oncology, Inc. (Prot #CG2003C)